The estimated Net Worth of Life Sciences Ix, L.P.Toppe... is at least $136 Million dollars as of 29 October 2019. Life Toppe owns over 1,052,631 units of Phathom Pharmaceuticals Inc stock worth over $136,215,830 and over the last 5 years Life sold PHAT stock worth over $0.
Life has made over 1 trades of the Phathom Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Life bought 1,052,631 units of PHAT stock worth $19,999,989 on 29 October 2019.
The largest trade Life's ever made was buying 1,052,631 units of Phathom Pharmaceuticals Inc stock on 29 October 2019 worth over $19,999,989. On average, Life trades about 1,052,631 units every 0 days since 2019. As of 29 October 2019 Life still owns at least 7,284,269 units of Phathom Pharmaceuticals Inc stock.
You can see the complete history of Life Toppe stock trades at the bottom of the page.
Over the last 5 years, insiders at Phathom Pharmaceuticals Inc have traded over $112,538,769 worth of Phathom Pharmaceuticals Inc stock and bought 2,393,679 units worth $45,337,731 . The most active insiders traders include Capital Management, L.P.Ra ..., James N Topper, and Pharmaceutical Co Ltd Takeda. On average, Phathom Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $2,226,815. The most recent stock trade was executed by Azmi Nabulsi on 15 July 2024, trading 10,901 units of PHAT stock currently worth $127,760.
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
Phathom Pharmaceuticals Inc executives and other stock owners filed with the SEC include: